Therapeutic Expertise
Infectious Diseases
Our team brings extensive expertise in infectious disease research, offering high-quality, flexible, and accelerated solutions tailored to the dynamic needs of global sponsors.
Conducting clinical trials in infectious diseases requires in-depth understanding of rapidly evolving pathogens, complex patient management, strict infection control, and the ability to respond swiftly to emerging threats.
We collaborate closely with infectious disease specialists and maintain strong partnerships with clinical sites globally to ensure rapid mobilisation and execution of trials.
Addressing common pain points in infectious diseases clinical trials
Biosafety and infection control
Trials in infectious diseases necessitate stringent biosafety measures to protect patients, staff, and communities.
We implement comprehensive infection control aligned with global biosafety standards, with thorough training and continuous monitoring across all sites.
Dynamic regulatory environment
Regulatory landscapes can change rapidly during outbreaks, complicating trial design and execution.
Our regulatory experts provide agile, proactive support, ensuring compliance and timely approvals even amid rapidly changing guidelines.
Complexity of outcome measures
Infectious diseases often involve multifaceted outcomes — viral load, immune response, clinical endpoints — complicating data collection.
Our experienced clinical team and centralised laboratories ensure standardised, accurate, and timely data collection and analysis.
Rapid patient recruitment and site activation
Outbreaks often require rapid response, making swift recruitment and site activation critical.
Our global network of pre-qualified sites with rapid start-up capabilities and advanced patient databases enable quick enrolment and timely initiation.
Safety and adverse event management
Trials of novel therapies or vaccines carry inherent safety risks requiring vigilant monitoring.
Advanced safety monitoring and real-time analytics, with a dedicated safety board, swiftly identify and manage potential adverse events.
Resources
Infectious Diseases clinical trial resources
HIV/AIDS
Navigating the complexities of HIV/AIDS clinical trials — diagnostic criteria, pivotal endpoints, and regulatory pathways.
Evidence & insights
Infectious Diseases white papers
Open-access reports from our physicians and data science teams — free, no sign-in.
Frequently asked questions
Infectious Diseases clinical trials — FAQs
What infectious disease programmes does iNGENū run?
Can iNGENū accelerate infectious disease trial start-up?
Is the data FDA-acceptable?
The iNGENū CRO difference
Australian expertise, direct FDA submission
We uniquely combine Australian expertise with direct FDA submission capabilities, offering a streamlined path for sponsors to achieve global approval. Trial data from Australia can be submitted directly to the FDA via our E-Gateway, eliminating the need for third-party intermediaries.
iNGENū takes a highly strategic and disciplined approach to clinical research, ensuring every dollar is directed toward generating meaningful outcomes — eliminating unnecessary costs while maintaining the highest scientific and regulatory standards across the Asia-Pacific region.
“We have been using iNGENū for a Phase 1, first-in-human trial of our investigational drug — medical writing, project management, clinical data management and full end-to-end execution and monitoring. We have been particularly impressed by the out-of-the-box creative solutions to speed up and reduce overheads during this clinical trial.”
Giles MossChief Executive Officer
Ready to discuss your Infectious Diseases clinical trial?
Talk to our team about how iNGENū CRO can accelerate your research.
Request a proposal